All In Biotech

Drug Trial Radar · NCT04147650

Dose Ranging Study to Assess the Efficacy and Safety of Voclosporin Ophthalmic Solution in Subjects With Dry Eye Syndrome

A Randomized, Double-Masked, Vehicle-Controlled, Dose Ranging Study to Assess the Efficacy and Safety of Voclosporin Ophthalmic Solution (VOS) in Subjects With Dry Eye Syndrome (DES)

Last checked: Nov 19, 2026Latest source record: Dec 10, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 508 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

508

Actual

Start

Oct 14, 2019

Primary completion

Sep 17, 2020

Study completion Oct 8, 2020

Sponsor

Lead sponsor
Aurinia Pharmaceuticals Inc.Industry
Sponsor type
Industry
First posted
Nov 1, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Multi-Center, Phase 2/3, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Clinical Trial to Assess the Safety and Efficacy of Voclosporin Ophthalmic Solution (0.05%, 0.10%, 0.20%) Compared to Vehicle in Subjects with Dry Eye Syndrome.

Conditions

  • Dry Eye Syndrome
  • Keratoconjunctivitis Sicca

Interventions

  • 0.05% Voclosporin Ophthalmic Solution (VOS)Drug

    0.05% VOS, in both eyes (OU) twice a day (BID) over 12 weeks

  • 0.10% VOSDrug

    0.10% VOS, in both eyes (OU) twice a day (BID) over 12 weeks

  • 0.20% VOSDrug

    0.20% VOS, in both eyes (OU) twice a day (BID) over 12 weeks

  • Vehicle Ophthalmic SolutionDrug

    Vehicle Ophthalmic Solution, in both eyes (OU) twice a day (BID) over 12 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Subjects With a ≥10 mm Increase From Baseline in Schirmer Tear Test (STT)Time frame: 4 Weeks

Locations

9 sites in 1 country. Site status is shown where the registry gives one.

  • Aurinia Investigative Center

    Newport Beach, California

  • Aurinia Investigative Center

    Colorado Springs, Colorado

  • Aurinia Investigative Center

    Louisville, Kentucky

  • Aurinia Investigative Center

    Lewiston, Maine

  • Aurinia Investigative Center

    Andover, Massachusetts

  • Aurinia Investigative Center

    Raynham, Massachusetts

  • Aurinia Investigative Center

    Cranberry Township, Pennsylvania

  • Aurinia Investigative Center

    Memphis, Tennessee

  • Aurinia Investigative Center

    Nashville, Tennessee

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.